Phase I study of nimotuzumab, a humanized anti-epidermal growth factor receptor (EGFR) IgG1 monoclonal antibody in patients with solid tumors in Japan

被引：0
|
作者：
Boku, N.
Yamazaki, K.
Yamamoto, N.
Takahashi, T.
Fukutomi, A.
Miyazaki, M.
Satoh, T.
Okamoto, I.
Nakagawa, K.
Fukuoka, M.
机构：
[1] Shizuoka Canc Ctr, Shizuoka, Japan
[2] Kinki Univ, Sch Med, Osaka 589, Japan
[3] Kinki Univ, Sakai Hosp, Osaka, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e14574
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A phase I study of farletuzumab, a humanized anti-folate receptor α monoclonal antibody, in patients with solid tumors
    Yasutsuna Sasaki
    Keisuke Miwa
    Keishi Yamashita
    Yu Sunakawa
    Ken Shimada
    Hiroo Ishida
    Kosei Hasegawa
    Keiichi Fujiwara
    Makoto Kodaira
    Yasuhiro Fujiwara
    Masayuki Namiki
    Minami Matsuda
    Yutaka Takeuchi
    Noriyuki Katsumata
    Investigational New Drugs, 2015, 33 : 332 - 340
  • [22] Feasibility of combining humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 (nimotuzumab) with chemotherapy-A study of toxicity profile and tolerance
    Pendharkar, D.
    Gupta, S.
    Pal, M. K.
    Hakim, S.
    Rashid, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [23] Pharmacodynamic study of nimotuzumab, an anti-epidermal growth factor receptor (EGFR) monoclonal antibody (MAb), in patients with unresectable squamous cell carcinoma of the head and neck (SCCHN): A SENDO Foundation study
    Rojo, F.
    Gracias, E.
    Villena, N.
    Cruz, T.
    Corradino, I.
    Cedeno, M.
    Campas, C.
    Sessa, C.
    Crombet, T.
    Albanell, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [24] A First-in-Human Phase I Study of GC1118, a Novel Anti-Epidermal Growth Factor Receptor Antibody, in Patients with Advanced Solid Tumors
    Oh, Do-Youn
    Lee, Keun-Wook
    Han, Sae-Won
    Kim, Jin Won
    Shin, Jung-Won
    Jo, Seong-Jin
    Won, Jonghwa
    Hahn, Seokyung
    Lee, Howard
    Kim, Woo Ho
    Bang, Yung-Jue
    ONCOLOGIST, 2019, 24 (08): : 1037 - +
  • [25] Hepatocellular carcinoma treated with anti-epidermal growth factor receptor antibody nimotuzumab A case report
    Song, Peng
    Yang, Jing
    Li, Xiaomei
    Huang, Haili
    Guo, Xueguang
    Zhou, Gang
    Xu, Xian
    Cai, Yi
    Zhu, Min
    Wang, Peng
    Zhao, Shu
    Zhang, Dong
    MEDICINE, 2017, 96 (39)
  • [26] A phase I study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with paclitaxel in patients with EGFR-positive advanced non-small-cell lung cancer (NSCLC)
    Kollmannsberger, C.
    Schittenhelm, M.
    Honecker, F.
    Tillner, J.
    Weber, D.
    Oechsle, K.
    Kanz, L.
    Bokemeyer, C.
    ANNALS OF ONCOLOGY, 2006, 17 (06) : 1007 - 1013
  • [27] Final results of a randomized phase I pharmacokinetic and pharmacodynamic study of weekly EMD 72000 (matuzumab), a humanized anti-epidermal growth factor receptor (EGFR) monoclonal antibody, in subjects with advanced gastroinestinal cancers
    Trarbach, Tanja
    Beyer, Thomas
    Schleucher, Norbert
    Stattaus, Jorg
    Mueller, Stefan P.
    Rojo, Federico
    Tillner, Joachim
    Schmid, Kurt W.
    Seeber, Siegfried
    Vanhoefer, Udo
    ANNALS OF ONCOLOGY, 2004, 15 : 101 - 101
  • [28] Phase I study of ramucirumab, a recombinant human IgG1 monoclonal antibody inhibiting vascular endothelial growth factor receptor-2, in Chinese patients with advanced solid tumors
    Li, Jin
    Cao, Junning
    Wang, Jin
    Li, Baoyue
    Chi, Haidong
    Gao, Ling
    CANCER RESEARCH, 2016, 76
  • [29] A randomised, open label phase III trial with nimotuzumab, an anti-epidermal growth factor receptor monoclonal antibody in the treatment of newly diagnosed adult glioblastoma
    Westphal, Manfred
    Heese, Oliver
    Steinbach, Joachim P.
    Schnell, Oliver
    Schackert, Gabriele
    Mehdorn, Maximilian
    Schulz, Dirk
    Simon, Matthias
    Schlegel, Uwe
    Senft, Christian
    Geletneky, Karsten
    Braun, Christian
    Hartung, Joachim G.
    Reuter, Dirk
    Metz, Monika Warmuth
    Bach, Ferdinand
    Pietsch, Torsten
    EUROPEAN JOURNAL OF CANCER, 2015, 51 (04) : 522 - 532
  • [30] Phase 1 clinical trial of ABX-EGF, a fully human anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) for patients with advanced cancer
    Figlin, R
    Belldegrun, A
    Crawford, J
    Lohner, M
    Roskos, L
    Yang, XD
    Foon, KA
    Schwab, G
    Weiner, L
    INTERNATIONAL JOURNAL OF CANCER, 2002, : 87 - 87
12345